Тектротид

Тектротид (Hynic-[d-Phe1,tyr3-Octreotide]*tfa) is a radiopharmaceutical used in diagnostic imaging procedures. This compound supports nuclear medicine applications for precise medical evaluations. Suitable for intravenous administration in clinical settings. Designed for compatibility with standard imaging protocols.

Тектротид is primarily used in nuclear medicine imaging to assist in the detection of certain types of tumors and other abnormalities. It is employed in procedures where radiolabeled peptides are required for diagnostic purposes. This compound is particularly useful in imaging studies involving somatostatin receptor-positive tissues. It supports the evaluation of conditions such as neuroendocrine tumors.

When administered intravenously, Тектротид binds to specific receptors in the body, enabling targeted imaging of tissues with high receptor density. The effects are typically observed during diagnostic imaging sessions, where the compound helps highlight areas of interest for medical professionals. Its use is confined to clinical environments under controlled conditions.

Тектротид should only be handled by trained medical personnel in approved clinical settings. Proper radiation safety protocols must be followed to minimize exposure risks. Patients should disclose any known allergies or sensitivities prior to administration. Storage and disposal must comply with local regulations for radiopharmaceuticals.

No specific drug interactions have been widely documented for Тектротид, as its use is confined to diagnostic imaging. However, patients should inform healthcare providers about all medications, supplements, or medical conditions before administration. Caution is advised when combining with other radiopharmaceuticals or imaging agents.